From the Boston Globe Business Team
Epix stops work on depression drug candidate
Email|
Text size
–
+
March 20, 2008 07:58 AM
Epix Pharmaceuticals Inc. of Lexington said today it is halting development of a potential treatment for depression following disappointing results in a clinical trial. 
The company said it is discontinuing clinical development of PRX-00023 "due to a lack of significant efficacy."
In its statement this morning, the company noted that its plan to get US approval of an imaging agent called Vasovist is "on track" - Vasovist has already won regulatory approval for marketing in 33 countries.
Epix also reported that it is "making important progress in its promising Alzheimer's disease program."
On the Nasdaq Stock Market yesterday, shares of Epix closed at $3.08, up 11 cents.
(By Chris Reidy, Globe staff)
rising
falling 